Champions Oncology (CSBR)
(Delayed Data from NSDQ)
$5.06 USD
+0.03 (0.60%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $5.03 -0.03 (-0.59%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CSBR 5.06 +0.03(0.60%)
Will CSBR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CSBR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CSBR
Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue Estimates
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates
CSBR: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates
Implied Volatility Surging for Champions Oncology (CSBR) Stock Options
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates
Other News for CSBR
Craig-Hallum downgrades Champions Oncology to Hold amid challenging environment
Craig-Hallum gets more bearish on Champions Oncology, downgrades shares
Champions Oncology, Inc. (CSBR) Q3 2024 Earnings Call Transcript
Earnings Scheduled For March 12, 2024
Champions Oncology Non-GAAP EPS of -$0.16, revenue of $12M